PMC:7033706 / 6147-6793 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"163","span":{"begin":451,"end":452},"obj":"Gene"},{"id":"164","span":{"begin":433,"end":434},"obj":"Gene"},{"id":"165","span":{"begin":12,"end":20},"obj":"Species"},{"id":"166","span":{"begin":25,"end":33},"obj":"Species"},{"id":"167","span":{"begin":176,"end":184},"obj":"Species"},{"id":"168","span":{"begin":281,"end":289},"obj":"Species"},{"id":"169","span":{"begin":423,"end":432},"obj":"Species"},{"id":"170","span":{"begin":466,"end":477},"obj":"Species"},{"id":"171","span":{"begin":508,"end":517},"obj":"Species"},{"id":"172","span":{"begin":572,"end":583},"obj":"Species"},{"id":"173","span":{"begin":590,"end":599},"obj":"Species"},{"id":"174","span":{"begin":189,"end":208},"obj":"Disease"},{"id":"175","span":{"begin":388,"end":401},"obj":"Disease"}],"attributes":[{"id":"A163","pred":"tao:has_database_id","subj":"163","obj":"Gene:43740568"},{"id":"A164","pred":"tao:has_database_id","subj":"164","obj":"Gene:43740568"},{"id":"A165","pred":"tao:has_database_id","subj":"165","obj":"Tax:694009"},{"id":"A166","pred":"tao:has_database_id","subj":"166","obj":"Tax:1335626"},{"id":"A167","pred":"tao:has_database_id","subj":"167","obj":"Tax:694009"},{"id":"A168","pred":"tao:has_database_id","subj":"168","obj":"Tax:1335626"},{"id":"A169","pred":"tao:has_database_id","subj":"169","obj":"Tax:2697049"},{"id":"A170","pred":"tao:has_database_id","subj":"170","obj":"Tax:11118"},{"id":"A171","pred":"tao:has_database_id","subj":"171","obj":"Tax:2697049"},{"id":"A172","pred":"tao:has_database_id","subj":"172","obj":"Tax:11118"},{"id":"A173","pred":"tao:has_database_id","subj":"173","obj":"Tax:2697049"},{"id":"A174","pred":"tao:has_database_id","subj":"174","obj":"MESH:D018352"},{"id":"A175","pred":"tao:has_database_id","subj":"175","obj":"MESH:D018352"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The RBDs of SARS-CoV and MERS-CoV contain multiple conformation-dependent neutralizing epitopes that induce more potent neutralizing antibodies and protective efficacy against SARS-CoV and MERS-CoV infections, respectively, than other regions in S protein [5,8,9]. Modification of MERS-CoV S-RBD amino acid residues based on the structure design could improve its protection against MERS-CoV infection [9], suggesting that 2019-nCoV S-RBD or modified S-RBD of other coronavirus may be applied for developing 2019-nCoV vaccines. Of course, the RBD-containing S and S1 of a coronavirus, e.g. 2019-nCoV, can also be used for vaccine development [8]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T20","span":{"begin":248,"end":255},"obj":"Body_part"},{"id":"T21","span":{"begin":296,"end":306},"obj":"Body_part"}],"attributes":[{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma82739"}],"text":"The RBDs of SARS-CoV and MERS-CoV contain multiple conformation-dependent neutralizing epitopes that induce more potent neutralizing antibodies and protective efficacy against SARS-CoV and MERS-CoV infections, respectively, than other regions in S protein [5,8,9]. Modification of MERS-CoV S-RBD amino acid residues based on the structure design could improve its protection against MERS-CoV infection [9], suggesting that 2019-nCoV S-RBD or modified S-RBD of other coronavirus may be applied for developing 2019-nCoV vaccines. Of course, the RBD-containing S and S1 of a coronavirus, e.g. 2019-nCoV, can also be used for vaccine development [8]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T26","span":{"begin":12,"end":20},"obj":"Disease"},{"id":"T27","span":{"begin":176,"end":184},"obj":"Disease"},{"id":"T28","span":{"begin":198,"end":208},"obj":"Disease"},{"id":"T29","span":{"begin":392,"end":401},"obj":"Disease"}],"attributes":[{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"The RBDs of SARS-CoV and MERS-CoV contain multiple conformation-dependent neutralizing epitopes that induce more potent neutralizing antibodies and protective efficacy against SARS-CoV and MERS-CoV infections, respectively, than other regions in S protein [5,8,9]. Modification of MERS-CoV S-RBD amino acid residues based on the structure design could improve its protection against MERS-CoV infection [9], suggesting that 2019-nCoV S-RBD or modified S-RBD of other coronavirus may be applied for developing 2019-nCoV vaccines. Of course, the RBD-containing S and S1 of a coronavirus, e.g. 2019-nCoV, can also be used for vaccine development [8]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T87","span":{"begin":296,"end":315},"obj":"http://purl.obolibrary.org/obo/CHEBI_33708"},{"id":"T88","span":{"begin":296,"end":315},"obj":"http://purl.obolibrary.org/obo/PR_000036907"},{"id":"T89","span":{"begin":564,"end":566},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T90","span":{"begin":570,"end":571},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The RBDs of SARS-CoV and MERS-CoV contain multiple conformation-dependent neutralizing epitopes that induce more potent neutralizing antibodies and protective efficacy against SARS-CoV and MERS-CoV infections, respectively, than other regions in S protein [5,8,9]. Modification of MERS-CoV S-RBD amino acid residues based on the structure design could improve its protection against MERS-CoV infection [9], suggesting that 2019-nCoV S-RBD or modified S-RBD of other coronavirus may be applied for developing 2019-nCoV vaccines. Of course, the RBD-containing S and S1 of a coronavirus, e.g. 2019-nCoV, can also be used for vaccine development [8]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T46","span":{"begin":248,"end":255},"obj":"Chemical"},{"id":"T47","span":{"begin":296,"end":306},"obj":"Chemical"},{"id":"T48","span":{"begin":296,"end":301},"obj":"Chemical"},{"id":"T49","span":{"begin":302,"end":306},"obj":"Chemical"}],"attributes":[{"id":"A46","pred":"chebi_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_33709"},{"id":"A48","pred":"chebi_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_46882"},{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"}],"text":"The RBDs of SARS-CoV and MERS-CoV contain multiple conformation-dependent neutralizing epitopes that induce more potent neutralizing antibodies and protective efficacy against SARS-CoV and MERS-CoV infections, respectively, than other regions in S protein [5,8,9]. Modification of MERS-CoV S-RBD amino acid residues based on the structure design could improve its protection against MERS-CoV infection [9], suggesting that 2019-nCoV S-RBD or modified S-RBD of other coronavirus may be applied for developing 2019-nCoV vaccines. Of course, the RBD-containing S and S1 of a coronavirus, e.g. 2019-nCoV, can also be used for vaccine development [8]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T34","span":{"begin":0,"end":264},"obj":"Sentence"},{"id":"T35","span":{"begin":265,"end":527},"obj":"Sentence"},{"id":"T36","span":{"begin":528,"end":646},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The RBDs of SARS-CoV and MERS-CoV contain multiple conformation-dependent neutralizing epitopes that induce more potent neutralizing antibodies and protective efficacy against SARS-CoV and MERS-CoV infections, respectively, than other regions in S protein [5,8,9]. Modification of MERS-CoV S-RBD amino acid residues based on the structure design could improve its protection against MERS-CoV infection [9], suggesting that 2019-nCoV S-RBD or modified S-RBD of other coronavirus may be applied for developing 2019-nCoV vaccines. Of course, the RBD-containing S and S1 of a coronavirus, e.g. 2019-nCoV, can also be used for vaccine development [8]."}